Adalimumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Moderate to Severe Plaque Psoriasis
Conditions
Moderate to Severe Plaque Psoriasis
Trial Timeline
May 1, 2012 → Sep 1, 2013
NCT ID
NCT01644396About Adalimumab
Adalimumab is a approved stage product being developed by AbbVie for Moderate to Severe Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01644396. Target conditions include Moderate to Severe Plaque Psoriasis.
What happened to similar drugs?
6 of 20 similar drugs in Moderate to Severe Plaque Psoriasis were approved
Approved (6) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05414201 | Approved | Completed |
| NCT04183608 | Approved | Recruiting |
| NCT03311464 | Phase 3 | Completed |
| NCT03261102 | Pre-clinical | Active |
| NCT02897115 | Approved | Terminated |
| NCT02904902 | Phase 3 | Completed |
| NCT02668640 | Pre-clinical | Completed |
| NCT02750800 | Pre-clinical | Completed |
| NCT02739828 | Pre-clinical | Completed |
| NCT02634541 | Approved | UNKNOWN |
| NCT02632175 | Phase 3 | Completed |
| NCT02533375 | Phase 3 | Completed |
| NCT02499783 | Phase 3 | Completed |
| NCT02198651 | Approved | Completed |
| NCT02333383 | Pre-clinical | Completed |
| NCT02539849 | Pre-clinical | Completed |
| NCT02185014 | Phase 3 | Completed |
| NCT02148718 | Approved | Completed |
| NCT02065622 | Phase 3 | Completed |
| NCT02016482 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Plaque Psoriasis